Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia.

BACKGROUND The receptor for advanced glycation end products (RAGE) is a cell surface receptor that has been implicated in vascular disease and neurodegeneration. Low levels of its secreted isoform, soluble RAGE (sRAGE), have been regarded as a putative risk factor for atherosclerosis. In addition, administration of sRAGE has been shown to reduce development of cerebral beta-amyloidosis in an Alzheimer disease mouse model. OBJECTIVE To investigate the role of sRAGE as a biological marker for Alzheimer disease and vascular dementia. DESIGN Cross-sectional study of 152 patients with a clinical diagnosis of Alzheimer disease, 91 with vascular dementia and 161 control subjects. MAIN OUTCOME MEASURE Plasma levels of sRAGE. RESULTS Levels of sRAGE were significantly reduced in the plasma of patients with Alzheimer disease compared with that for those with either vascular dementia (P<.05) or with controls (P<.001). CONCLUSIONS Patients with Alzheimer disease have reduced levels of sRAGE in plasma compared with patients with vascular dementia and controls. The striking reduction of circulating sRAGE in Alzheimer disease further supports a role for the RAGE axis in this clinical entity and requires further investigation.

[1]  A. D'Angelo,et al.  Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Coronary Artery Disease in Nondiabetic Men , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[2]  R. Deane,et al.  RAGE (Yin) Versus LRP (Yang) Balance Regulates Alzheimer Amyloid &bgr;-Peptide Clearance Through Transport Across the Blood–Brain Barrier , 2004, Stroke.

[3]  R. Ramasamy,et al.  RAGE Axis: Animal Models and Novel Insights Into the Vascular Complications of Diabetes , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[4]  R. Mayeux,et al.  Cardiovascular risk factors and Alzheimer’s disease , 2004, Current atherosclerosis reports.

[5]  Jeon-Soo Shin,et al.  Expression of a novel secreted splice variant of the receptor for advanced glycation end products (RAGE) in human brain astrocytes and peripheral blood mononuclear cells. , 2004, Molecular immunology.

[6]  Ann Marie Schmidt,et al.  RAGE mediates amyloid-β peptide transport across the blood-brain barrier and accumulation in brain , 2003, Nature Medicine.

[7]  A. Schmidt,et al.  Receptor for advanced glycation endproducts: a multiligand receptor magnifying cell stress in diverse pathologic settings. , 2002, Advanced drug delivery reviews.

[8]  A. Schmidt,et al.  RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease , 2002, Cellular and Molecular Life Sciences CMLS.

[9]  T. Erkinjuntti,et al.  Diagnosis and management of vascular cognitive impairment and dementia. , 2002, Journal of neural transmission. Supplementum.

[10]  A. Schmidt,et al.  The biology of the receptor for advanced glycation end products and its ligands. , 2000, Biochimica et biophysica acta.

[11]  D. T. Vernier,et al.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.